Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has reported fourth quarter profit of $17-million or 69 cents a share, compared with $1.5-million or 6 cents in the 2012 quarter. Revenue rose to $12.5-million from $2.9-million. “Strong performance from Absorica, including a sales milestone we achieved in the fourth quarter, helped drive significant revenue and earnings growth in […]
Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has appointed Gerald McDole as chairman, effective immediately, replacing William Garriock, who resigned on Dec. 31, 2013. Mr. McDole has been a member of the Cipher board since 2004. He retired as president and CEO of AstraZeneca Canada’s pharmaceutical operations at the end of 2003.
Tweet Cipher Pharmaceuticals’ (OTCBB:CPHMF; TSX:DND) marketing partner for Absorica has reached a cumulative sales milestone in accordance with the parties’ commercial agreement, triggering a one-time $5-million payment to Cipher. The company said the revenue would be included in its fourth quarter 2013 financial results, which it plans to report in late February. Absorica is an […]
Tweet William Garriock, chairman of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), is retiring from active business and has resigned as chairman, effective tomorrow. “On behalf of the board, i would like to thank Bill for his service and contributions, and wish him well in retirement,” CEO Larry Andrews said in a statement.
Tweet Third quarter net income for Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) rose to $3.4-million, or 14 cents a share, from $754,000, or 3 cents, in the year earlier quarter. Net revenue climbed to $5.6-million from $2.1-million. “Absorica performed well again in the third quarter, with market share increasing to 17.3% by September from 13.1% in June, […]
Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), in response to questions from shareholders about a Paragraph IV Certification received by its U.S. marketing partner, Ranbaxy Laboratories, has posted on its website some of the most frequently asked questions and Cipher’s response. The Q&A can be accessed here.
Tweet As a result of its annual review, S&P Dow Jones Canadian Index Services is making changes to the S&P/TSX SmallCap Index at the close of trading this Friday, with Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) replacing CML Healthcare Inc.
Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has reported net income of $3.1-million or 13 cents a share on revenue of $5.5-million for the second quarter, compared with $200,000 or 1 cent on revenue of $1.6-million a year earlier. “The continued strong growth of Absorica drove significant gains in our revenue, earnings and cash for the second […]
Tweet At the annual Canadian Dermatology Association Conference in Quebec City over the July 1 weekend, Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) announced the Canadian launch of Epuris, a novel brand formulation of the acne medication isotretinoin for the treatment of severe acne in patients aged 12 years or older. “This represents an important milestone on the path […]
Tweet Byron Capital Markets has raised its price target on “buy-rated” Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) to $6.25 from $5.25, after the company posted record results for the first quarter. The stock closed at $3.80 on Friday. “Our key takeaway is the Absorica launch is outperforming even our optimistic expectations,” writes analyst Doug Loe. On Absorica’s […]